Save The Date: Molecure to Host Virtual R&D Day on 7th December 2022
Warsaw, Poland – 14 November 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, will host a virtual R&D Day on the 7th December 2022 at 13.30 CET / 12.30 BST / 7.30 ET.
During this event, management and scientific leaders will provide a comprehensive review of Molecure’s the company’s pipeline.
The event will provide updates on Molecure’s clinical development plans and related near-term catalysts, with a focus on its two novel drug candidates, OATD-01, a first in class chitinase inhibitor for sarcoidosis and OATD-02, a dual acting, highly potent arginase inhibitor for a broad range of cancers.
Date: 7th December 2022
Time: 13.30 - 16.30 CET
The agenda and details of how to join the meeting will be available in an invitation and on the Company’s website (www.molecure.com) which will be issued closer to the time of the event.